Clinical Trial Update: Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality. [Phase 2]

View source ↗

Summary

A completed Phase 2 trial evaluating lenalidomide in patients with low- and intermediate-1 risk myelodysplastic syndromes without chromosome 5 abnormalities.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: Groupe Francophone des Myelodysplasies | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED